Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
German economic institutes cut forecast in half over Iran war - 2Find the Advantages of Innovative Leisure activities: Supporting Creative mind and Self-Articulation
- 3Last supermoon of the year, the cold moon, seen across the U.S.: See the photos
- 4Three arrested in Paris after attempted bomb attack outside Bank of America
- 5Evaluated Smartwatches for Wellness Devotees
- CVS forecasts 2026 profit above estimates on strong performance
- From Educational Loans to Obligation Free: Independence from the rat race Accomplished
- The Eastern Bongo, Kenya’s Rare Forest Antelope on the Brink
- The Development of Shipping: Controlling Towards a More Associated Future
- Figure out How to Upgrade Your Gold Speculation Portfolio: Vital Bits of knowledge and Strategies
- Moon milestones: A rundown of Artemis 2's many spaceflight firsts
- Watch Blue Origin's huge New Glenn rocket ace its epic landing on a ship at sea (video)
- 4 Masked Men Steal Renoir, Matisse and Cézanne Paintings Worth Over $10 Million in 3-Minute Heist
- Limited Rain Chances in Brazil Boost Coffee Prices
